Home
Kjell-Morten Myhr's picture

Kjell-Morten Myhr

Head of Department
  • E-mailKjell-Morten.Myhr@uib.no
  • Phone+47 55 97 60 31+47 414 47 868
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2019. The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS). Multiple Sclerosis and Related Disorders. 1-6.
  • Show author(s) 2019. The Association Between Exposure to Interferon-Beta During Pregnancy and Birth Measurements in Offspring of Women With Multiple Sclerosis. PLOS ONE. 1-10.
  • Show author(s) 2019. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Multiple Sclerosis. 1-9.
  • Show author(s) 2018. α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis. 987-993.
  • Show author(s) 2018. The economic impact of multiple sclerosis to the patients and their families in Norway. European Journal of Health Economics. 1243-1257.
  • Show author(s) 2018. Shedding light on the link between early life sun exposure and risk of multiple sclerosis: results from the EnvIMS Study . International Journal of Epidemiology. 1073-1082.
  • Show author(s) 2018. Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. Journal of Neuroimmunology. 73-77.
  • Show author(s) 2018. Neurofilaments and 10-year follow-up in multiple sclerosis. Multiple Sclerosis. 1301-1307.
  • Show author(s) 2018. Multiple sclerosis registries in Europe – An updated mapping survey. Multiple Sclerosis and Related Disorders. 171-178.
  • Show author(s) 2018. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell. 1679-1687.
  • Show author(s) 2017. The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway. Seizure. 131-135.
  • Show author(s) 2017. Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. Journal of Neurology, Neurosurgery and Psychiatry. 621-625.
  • Show author(s) 2017. Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis. 150-157.
  • Show author(s) 2017. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 1-8.
  • Show author(s) 2017. Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. Multiple Sclerosis. 213-219.
  • Show author(s) 2017. In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. Journal of Proteome Research. 179-194.
  • Show author(s) 2017. Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. NPJ GENOMIC MEDICINE. 12 pages.
  • Show author(s) 2017. Body size and physical exercise, and the risk of multiple sclerosis. Multiple Sclerosis. 270-278.
  • Show author(s) 2017. An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy. 1627-1635.
  • Show author(s) 2017. 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International. 262-277.
  • Show author(s) 2016. WT1 and interferon-β–vitamin D association in MS: a longitudinal study. Acta Neurologica Scandinavica. 309-312.
  • Show author(s) 2016. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology. 1064-1070.
  • Show author(s) 2016. The influence of coping styles on long-term employment in multiple sclerosis: A prospective study. Multiple Sclerosis. 1008-1017.
  • Show author(s) 2016. Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom. Annals of Neurology. 616-624.
  • Show author(s) 2016. No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and neuroinflammation. 5 pages.
  • Show author(s) 2016. Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. Multiple Sclerosis. 1018-1024.
  • Show author(s) 2016. Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. Multiple Sclerosis. 104-111.
  • Show author(s) 2016. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
  • Show author(s) 2016. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion (Amsterdam. Print). 32-35.
  • Show author(s) 2016. Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case-control study. European Journal of Neurology. 168-174.
  • Show author(s) 2016. Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology. 18-27.
  • Show author(s) 2016. CSF-PR 2.0: an interactive literature guide to quantitative cerebrospinal fluid mass spectrometry data from neurodegenerative disorders. Molecular & Cellular Proteomics. 300-309.
  • Show author(s) 2016. Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood. BMC Genetics.
  • Show author(s) 2016. Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts. CNS Drugs. 33-50.
  • Show author(s) 2016. A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. Multiple Sclerosis. 100-105.
  • Show author(s) 2015. Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 21-28.
  • Show author(s) 2015. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis. 1856-1864.
  • Show author(s) 2015. The EnvIMS study: Design and methodology of an international case-control study of environmental risk factors in multiple sclerosis. Neuroepidemiology. 173-181.
  • Show author(s) 2015. Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study. Journal of Neurology. 1271-1277.
  • Show author(s) 2015. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
  • Show author(s) 2015. Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
  • Show author(s) 2015. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain. 632-643.
  • Show author(s) 2015. Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology. 92-97.
  • Show author(s) 2014. Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Multiple Sclerosis. 1042-1049.
  • Show author(s) 2014. Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Multiple Sclerosis. 669-674.
  • Show author(s) 2014. Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. Journal of Neuroimmunology. 174-179.
  • Show author(s) 2014. Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 141-144.
  • Show author(s) 2014. Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology. 60-65.
  • Show author(s) 2014. In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Molecular & Cellular Proteomics. 3152-3163.
  • Show author(s) 2014. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
  • Show author(s) 2014. Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurologica Scandinavica. 21-26.
  • Show author(s) 2014. Employment among patients with multiple sclerosis-A population study. PLOS ONE.
  • Show author(s) 2014. Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
  • Show author(s) 2014. Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
  • Show author(s) 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE.
  • Show author(s) 2014. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry. 1109-1115.
  • Show author(s) 2014. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis. 1833-1840.
  • Show author(s) 2013. Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. Journal of Neurology. 1481-1488.
  • Show author(s) 2013. Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLOS ONE. 9 pages.
  • Show author(s) 2013. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Annals of Neurology. 430-432.
  • Show author(s) 2013. Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLOS ONE. 9 pages.
  • Show author(s) 2013. Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica. 16-23.
  • Show author(s) 2013. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No. Multiple Sclerosis. 1692-1693.
  • Show author(s) 2013. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis. 1074-1083.
  • Show author(s) 2013. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. Journal of Proteomics. 312-325.
  • Show author(s) 2013. Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
  • Show author(s) 2013. Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. PLOS ONE. 5 pages.
  • Show author(s) 2013. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis. 1533-1538.
  • Show author(s) 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics. 1353-1360.
  • Show author(s) 2013. Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLOS ONE. 5 pages.
  • Show author(s) 2013. A ‘‘candidate-interactome’’ aggregate analysis of genome-wide association data in multiple sclerosis. PLOS ONE.
  • Show author(s) 2012. ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. Archives of Neurology. 1044-1051.
  • Show author(s) 2012. Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurologica Scandinavica. 63-69.
  • Show author(s) 2012. Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 267-273.
  • Show author(s) 2012. The cuprizone model: regional heterogeneity of pathology. APMIS - Journal of Pathologiy, Microbiology and Immunology. 648-657.
  • Show author(s) 2012. The cost of multiple sclerosis in Norway. European Journal of Health Economics. 81-91.
  • Show author(s) 2012. The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 20-23.
  • Show author(s) 2012. Poor Sleep in Patients with Multiple Sclerosis. PLOS ONE. 5 pages.
  • Show author(s) 2012. Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course. Journal of Neuroimmunology. 107-110.
  • Show author(s) 2012. Month of birth as a risk factor for multiple sclerosis: an update. Acta Neurologica Scandinavica. 58-62.
  • Show author(s) 2012. Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients. Neuroepidemiology. 84-93.
  • Show author(s) 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 1116-1124.
  • Show author(s) 2012. Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Acta Neurologica Scandinavica, Supplementum. 84-89.
  • Show author(s) 2012. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurologica Scandinavica. 90-96.
  • Show author(s) 2012. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. Acta Neurologica Scandinavica. 24-30.
  • Show author(s) 2012. A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q). Acta Neurologica Scandinavica, Supplementum. 43-50.
  • Show author(s) 2012. A need for national registries and international collaborative research in multiple sclerosis. Acta Neurologica Scandinavica. 1-3.
  • Show author(s) 2011. Risk of MS is not associated with exposure to crude oil, but increases with low level of education. Multiple Sclerosis. 780-787.
  • Show author(s) 2011. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis. 1074-1078.
  • Show author(s) 2011. How long can you keep working with benign multiple sclerosis? Journal of Neurology, Neurosurgery and Psychiatry. 78-82.
  • Show author(s) 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 214-219.
  • Show author(s) 2011. Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance. European Journal of Neurology. 114-120.
  • Show author(s) 2011. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLOS ONE. 8 pages.
  • Show author(s) 2011. Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. European Journal of Human Genetics. 1100-1103.
  • Show author(s) 2010. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
  • Show author(s) 2010. Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29). Acta Neurologica Scandinavica. 244-251.
  • Show author(s) 2010. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. In Vivo. 185-188.
  • Show author(s) 2010. Norwegian Sami differs significantly from other Norwegians according to their HLA profile. Tissue Antigens. 207-217.
  • Show author(s) 2010. Benign multiple sclerosis: a need for a consensus. Acta Neurologica Scandinavica. 44-50.
  • Show author(s) 2010. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. European Journal of Human Genetics. 502-504.
  • Show author(s) 2010. A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. Journal of Proteome Research. 3608-3620.
  • Show author(s) 2008. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Archives of Neurology. 809-811.
  • Show author(s) 2008. Environmental risk factors in multiple sclerosis. Acta Neurologica Scandinavica. 34-40.
  • Show author(s) 2008. Diagnosis and treatment of multiple sclerosis. Acta Neurologica Scandinavica. 12-21.
  • Show author(s) 2007. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Multiple Sclerosis. 106-112.
  • Show author(s) 2007. Patient information and coping styles in multiple sclerosis. Multiple Sclerosis. 792-799.
  • Show author(s) 2007. Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurologica Scandinavica. 46-50.
  • Show author(s) 2007. Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis. 386-392.
  • Show author(s) 2007. Familial effects on the clinical course of multiple sclerosis. Neurology. 376-383.
  • Show author(s) 2006. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurologica Scandinavica. 51-54.
  • Show author(s) 2006. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurologica Scandinavica. 51-54.
  • Show author(s) 2006. Multippel sklerose. Norsk tidsskrift for logopedi. 5-9.
  • Show author(s) 2006. Balance and gait improved in patients with MS after physiotherapy based on the Bobath concept. Physiotherapy Research International. 104-116.
  • Show author(s) 2006. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology. 182-186.
  • Show author(s) 2005. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 1961-1963.
  • Show author(s) 2005. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatrica Scandinavica. 463-468.
  • Show author(s) 2005. Mild depression in young adults with cerebral infarction at long-term follow-up: A population-based study. European Journal of Neurology. 194-198.
  • Show author(s) 2005. Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. Journal of Neuroimmunology. 5 pages.
  • Show author(s) 2005. Fc gamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 277-282.
  • Show author(s) 2005. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovascular Diseases. 245-250.
  • Show author(s) 2005. Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. Scandinavian Journal of Immunology. 71-74.
  • Show author(s) 2005. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology. 416-421.
  • Show author(s) 2005. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology. 416-421.
  • Show author(s) 2005. Ethnic Variations of IL-10 Polymorphisms in a Sami and Norwegian Population. Scandinavian Journal of Immunology. 71-74.
  • Show author(s) 2005. Do all young ischemic stroke patients need long-term secondary preventive medication? Neurology. 609-611.
  • Show author(s) 2004. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 706-710.
  • Show author(s) 2004. Long-term outcome of cerebral infarction in young adults. Acta Neurologica Scandinavica. 107-112.
  • Show author(s) 2004. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens. 237-247.
  • Show author(s) 2004. Etiology of and risk factors for cerebral infarction in young adults in western Norway: a population-based case-control study. European Journal of Neurology. 25-30.
  • Show author(s) 2004. Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Multiple Sclerosis. 5-8.
  • Show author(s) 2001. Reduced quality of life among MS patients with sexual disturbance and bladder dysfunction. Multiple Sclerosis. 231-235.
  • Show author(s) 2001. Quality of life as a predictor for change in disability in MS reply (letter). Neurology. 1250.
  • Show author(s) 2000. Quality of life as a predictor for change in disability in multiple sclerosis. Neurology. 51-54.
  • Show author(s) 2000. Performens of the SF-36, SF-12 and RAND-36 summary scales in a multiple sclerosis population. Medical Care. 1022-1028.
  • Show author(s) 1999. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Multiple Sclerosis. 317-322.
  • Show author(s) 1999. Quality of life in multiple sclerosis: Measuring the disease effects more broadly. Neurology. 1091-1103.
Academic lecture
  • Show author(s) 2015. Vitamin D og interferon-behandling ved multippel sklerose.
  • Show author(s) 2015. Evidence of preclinical disease activity­ a prospective study on cognitive and physical performance prior to first symptom of multiple sclerosis.
  • Show author(s) 2014. Level of education and multiple sclerosis risk after adjustment for known risk factors: the EnvIMS study.
  • Show author(s) 2007. Target projection and proper data pre-treatment for the analysis of proteomic profiles.
  • Show author(s) 2007. Preteatment of Mass Spectral Profiles: Application to proteomic data.
  • Show author(s) 2007. Analysis of Proteomic Profiles.
  • Show author(s) 2006. Costs and quality of life in patients with multiple sclerosis in Norway compared to 9 other European countries.
  • Show author(s) 2000. Reduced quality of life among MS patients with sexual disturbance and bladder dysfunction.
  • Show author(s) 2000. Quality of life as a predictor for change in disability in multiple sclerosis.
  • Show author(s) 2000. Livskvalitet hos multippel sklerose pasienter - en utfordring for sykepleien.
  • Show author(s) 2000. Livskvalitet hos multippel sklerose pasienter.
  • Show author(s) 1999. The quality of life of multiple sclerosis patients in a treatment trial with recombinant interferon-alfa-2a.
  • Show author(s) 1999. Lack of agreement between objective disease measures and the Quality of Life in a treatment trial in multiple sclerosis.
  • Show author(s) 1999. Expanded Disability Status Scale scores and the Quality of Life of Multiple Sclerosis patients. An epidemiological study.
Abstract
  • Show author(s) 2017. alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. Multiple Sclerosis. 712-712.
  • Show author(s) 2017. Cancer risk in multiple sclerosis. Multiple Sclerosis. 486-487.
  • Show author(s) 2013. Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. Multiple Sclerosis. 33-34.
  • Show author(s) 2013. Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. Multiple Sclerosis. 400-400.
  • Show author(s) 2012. WalkAide - A multidisciplinary model for adjustment and evaluation. Multiple Sclerosis. S30-S30.
  • Show author(s) 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • Show author(s) 2012. Poor sleep in patients with multiple sclerosis. European Journal of Neurology. 706-706.
  • Show author(s) 2012. Overweight as a risk factor for multiple sclerosis. European Journal of Neurology. 353-353.
  • Show author(s) 2012. Norwegian quality registry for biological drugs: the NOKBIL project. Scandinavian Journal of Rheumatology. 50-50.
  • Show author(s) 2012. An age at exposure effect between sun exposure and the risk of MS in Norway and Italy. Multiple Sclerosis. s15-s15.
  • Show author(s) 2011. VITAMIN D, LIFESTYLE FACTORS AND RISK OF MULTIPLE SCLEROSIS. European Journal of Neurology. 16-16.
  • Show author(s) 2011. The Risk of Multiple Sclerosis Among Petroleum Workers Exposed to Crude Oil and Other Hydrocarbons. Epidemiology. S60-S60.
  • Show author(s) 2010. Trend of association to the Glypican 5 gene region to multiple sclerosis. European Journal of Neurology. 221-221.
  • Show author(s) 2010. The definition of benign multiple sclerosis: a methodical approach. European Journal of Neurology. 494-494.
  • Show author(s) 2009. Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. Multiple Sclerosis. S5-S5.
  • Show author(s) 2009. International case control study on risk factors for multiple sclerosis (MS): pilot testing the questionnaire. Multiple Sclerosis. 1403-1403.
  • Show author(s) 2009. Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
  • Show author(s) 2009. Fatigue in multiple sclerosis is associated with self-perceived health, but less with physical performance. Multiple Sclerosis. S225-S225.
  • Show author(s) 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • Show author(s) 2008. Gait and balance improved in patients with multiple sclerosis after inpatient physiotherapy. Multiple Sclerosis. S152-S152.
  • Show author(s) 2008. Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. Multiple Sclerosis. S90-S91.
  • Show author(s) 2008. Early diagnosis and biomarker discovery from mass spectral profiles: application to multiple sclerosis. Multiple Sclerosis. S285-S285.
  • Show author(s) 2008. Biomarker discovery from mass spectral profiles: A combined proteomics and multivariate analysis. European Journal of Pharmaceutical Sciences. S27-S27.
  • Show author(s) 2008. An international case-control study of risk factors for multiple sclerosis. Multiple Sclerosis. S197-S197.
  • Show author(s) 2008. Acceptability and cross-cultural feasibility of it self-administered questionnaire on past exposure to putative environmental risk factors for multiple sclerosis. Multiple Sclerosis. S196-S196.
  • Show author(s) 2007. Smoking habits in pregnant MS women. European Journal of Neurology. 278-278.
  • Show author(s) 2007. Perinatal factors and later development of multiple sclerosis. Multiple Sclerosis. S91-S92.
  • Show author(s) 2007. Individualised physiotherapy improved fatigue score in patients with multiple sclerosis. Multiple Sclerosis. S127-S127.
  • Show author(s) 2007. Increasing prevalence of multiple sclerosis in the elderly in western Norway. Multiple Sclerosis. S96-S96.
  • Show author(s) 2006. The role of SH2D2A gene polymorphisms in multiple sclerosis. Multiple Sclerosis. S72-S72.
  • Show author(s) 2006. The role of SH2D2A gene polymorphisms in development of multiple sclerosis. Tissue Antigens. 528-529.
  • Show author(s) 2006. Pregnancy, delivery and birth outcome in mothers prior to debut of multiple sclerosis. European Journal of Neurology. 28-29.
  • Show author(s) 2006. Low prevalence of multiple sclerosis in a Sami population is related to low frequency of the disease-associated HLA DR15-DQ6 haplotype. Tissue Antigens. 523-523.
  • Show author(s) 2006. Low prevalence of multiple sclerosis and the HLA CR15-DQ6 halotype in Sami. Multiple Sclerosis. 71-71.
  • Show author(s) 2006. Health-related quality of life in secondary progressive multiple sclerosis. European Journal of Neurology. 27-27.
  • Show author(s) 2005. The CD28/CTLA4/ICOS gene region does not show assosiation in Norwegian multiple sclerosis patients. Genes and Immunity. 1 pages.
Academic literature review
  • Show author(s) 2020. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders. 1-10.
  • Show author(s) 2020. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. Journal of Neurology. 15 pages.
  • Show author(s) 2019. Neurofilament light chain as a biomarker in multiple sclerosis. Frontiers in Neurology. 1-6.
  • Show author(s) 2019. B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy. 261-271.
  • Show author(s) 2017. Progressive multifocal leukoencephalopathy. Tidsskrift for Den norske legeforening. 10 pages.
  • Show author(s) 2015. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurologica Scandinavica. 29-36.
  • Show author(s) 2015. The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 24-28.
  • Show author(s) 2014. Multiple sclerosis registries in Europe - Results of a systematic survey. Multiple Sclerosis. 1523-1532.
  • Show author(s) 2014. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology. 1210-1216.
  • Show author(s) 2013. Neuromyelitis optica. Tidsskrift for Den norske legeforening. 2057-2061.
  • Show author(s) 2013. Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. Acta Neurologica Scandinavica, Supplementum. 24-30.
  • Show author(s) 2012. Polyunsaturated fatty acids in multiple sclerosis therapy. Acta Neurologica Scandinavica. 70-75.
  • Show author(s) 2009. Corticosteroids in the treatment of multiple sclerosis. Acta Neurologica Scandinavica. 73-80.
  • Show author(s) 2003. New diagnostic criteria in multiple sclerosis. Tidsskrift for Den norske legeforening. 1345-1348.

More information in national current research information system (CRIStin)